Pfizer to Lay Off 151 in Pearl River Vaccines Phase-Out
Pearl River had set the scene for vaccine breakthroughs, cGMP challenges, and ambitious Lean and operational excellence programs
Pfizer will lay off 151 workers at its facility in Pearl River, New York, according to local news report from Rockland County’s The Journal News. The layoffs will occur between August 20th and October 28th, The Journal News reported, and will affect 103 non-union and 48 union employees.
Plans for the layoffs, and the phase out of vaccine development and manufacturing at Pearl River, had been announced in 2009, after Pfizer’s acquisition of Wyeth Pharmaceuticals, former owner of the site.
Pearl River had been a setting for major breakthroughs and challenges for Wyeth, including development of the Prevnar pneumococcal vaccine, as well as a 2000 consent decree for manufacturing and quality issues. Following resolution of issues highlighted in the consent decree, Lean and Toyota Production System-inspired operational excellence and safety programs at the site had become benchmarks for pharmaceutical manufacturing. Reports say that 700 employees will remain on the site, working in cancer drug development and production. The site once employed 4,000.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Prokaryotics Licenses Gram-Negative Antibiotic Potentiator from Northern Antibiotics
June 26th 2025Prokaryotics will gain worldwide rights to develop, manufacture, and commercialize NAB741, a non-bioactive polymyxin designed to increase permeability of the outer membrane of Gram-negative bacteria.
